Marker Therapeutics, Inc. (MRKR)
MRKRNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$0.9361
+0.1021 (+12.24%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $14.51m
- P/E
- –
- EPS, last 4 quarters
- $-0.4100
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.8700 to $2.46
- Average volume
- –
- Previous close
- $0.8340
Analysts
2 coveringStrong Buy2 buy, 0 hold, 0 sell
Targets a year out average $9.00, +861.4% from here
Earnings
next estimate $-0.1200Next report
Sep 2025
+82.6%
Dec 2025
+81.0%
Mar 2026
+11.1%
Jun 2026
+64.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $2.44m | $1.10m | – | – |
| Gross profit | $2.44m | $1.10m | – | – |
| Operating income | -$926.0k | -$1.88m | -$4.07m | -$2.62m |
| Net income | -$2.00m | -$1.70m | -$3.18m | -$1.83m |
News
8 latest- Rigel Pharmaceuticals (RIGL) Misses Q3 Earnings EstimatesZacks · Nov 5, 2026
- Marker Therapeutics Secures $2.6 Mln FDA Grant To Support Phase 1 Of Pancreatic Cancer Study RTTNews · Oct 19, 2026
- All You Need to Know About MARKER THERAPEUTICS (MRKR) Rating Upgrade to Strong BuyZacks · Oct 16, 2026
- New Strong Buy Stocks for October 16thZacks · Oct 16, 2026
- Marker Highlights Expanded Manufacturing Support For MT-601 RTTNews · Sep 22, 2026
- Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings EstimatesZacks · Aug 6, 2026
- Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker Zacks · Jun 26, 2026
- 5 Small Drug Stocks to Invest in Amid a Biotech ComebackZacks · Jun 25, 2026
The company
Marker Therapeutics, Inc. is a Houston, TX-based clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors. The Company was founded at Baylor College of Medicine, and clinical trials that enrolled more than 200 patients across various hematological and solid tumor indications showed that the Company's autologous and allogeneic MAR-T cell products were well tolerated and demonstrated durable clinical responses. Marker's goal is to introduce novel T cell therapies to the market and improve patient outcomes. To achieve these objectives, the Company prioritizes the preservation of financial resources and focuses on operational excellence.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- markertherapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.